Our Research Members
Professor, Departments of Medicine and Nutritional Sciences, Faculty of Medicine
Director of Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
61 Queen Street East, 6th Floor, Room 6133Q
Toronto, ON M5C 2T2
Dr. Jenkins research area is the use of diet in the prevention and treatment of hyperlipidemia and diabetes. He has over 200 original publications on these and related topics. His team was the first to define and explore the concept of the glycemic index of foods and demonstrate the breadth of metabolic effects of viscous soluble fiber, including blood glucose and cholesterol lowering. His studies on combining cholesterol lowering food components (dietary portfolio) have been recognized as creating an effective dietary alternative to drug therapy (statins) for many people and was the only dietary approach referenced in the update of the guidelines of the US National Cholesterol Education Program (ATP III).
Professor, Department of Medicine, Division of Endocrinology & Metabolism
101 College Street, Room 10-354
Toronto, ON M5G 1L7
A) Mechanisms Underlying the Production and Function of the Incretin Hormone GLP-1. The proglucagon gene (Gcg) encodes three major peptide hormones, namely glucagon (produced in pancreas), glucagon-like peptide-1 (GLP-1) and GLP-2 (both are produced mainly in intestines). These hormones exert opposite or overlapping functions in controlling blood homeostasis, food intake, cell growth and proliferation. Based on the features of GLP-1, two new categories of drugs, namely GLP-1 analogues and DPP-IV inhibitors, have been developed for T2D treatment. We are exploring mechanisms underlying the production and function of peptide hormones encoded by Gcg, including GLP-1. We are now studying the role of Wnt signalling and the crosstalk between Wnt and other signalling pathways in regulating the expression and function of GLP-1.
B) Mechanisms Underlying the Expression and Function of the Lipogenic Gene Carbohydrates Response Element Binding Protein (ChREBP). The transcription factor ChREBP is a “master controller” of lipogenic genes that encode a battery of enzymes for converting carbohydrates into lipids. The function of ChREBP can be turned on by hyperglycemia and its expression was shown to be increased in obesity and hyperinsulinemia animal models. We are studying molecular mechanisms underlying the expression of ChREBP and its targets.
Professor of Medicine and Nutritional Sciences
Division of Endocrinology and Metabolism, St. Michael’s Hospital
61 Queen St. East, 6th Floor, Suite 6122
Toronto, ON M5C 2T2
Often with an emphasis in clinical nutrition, I have obtained peer review and non peer review grants (mostly Phase II and III pharmaceutically funded multicentre national and international studies) as Principal, Co-principal or Co-investigator. These studies have investigated the effects of various new drugs on diabetes control, hyperlipidemia and prevention and treatment of diabetes complications. I have been particularly interested in the nutritional management of diabetes with other colleagues in the Department of Nutritional Sciences (Jenkins, Wolever). We have promulgated the concept of the glycemic index of foods and the importance of meal frequency as therapeutic principles.